Collegium Pharmaceutical (COLL) director sells 4,500 shares in market trade

Rhea-AI Filing Summary

Collegium Pharmaceutical director Nancy Lurker reported an open-market sale of Common Stock. On May 13, 2026, she sold 4,500 shares at a weighted average price of $35.9691 per share, in multiple trades between $35.55 and $36.50. After this transaction, she directly holds 18,017 shares of Collegium Pharmaceutical common stock.

Insider Trade Summary

Net Seller: 4,500 shares ($161,861)

Net Sell 1 txn

Insider Lurker Nancy

Role null

Sold 4,500 shs ($162K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,500	$35.9691	$162K

Holdings After Transaction: Common Stock — 18,017 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 4,500 shares Weighted average sale price: $35.9691 per share Post-transaction holdings: 18,017 shares +1 more

4 metrics

Shares sold 4,500 shares Open-market sale on May 13, 2026

Weighted average sale price $35.9691 per share Common Stock sale on May 13, 2026

Post-transaction holdings 18,017 shares Direct ownership after the sale

Trade price range $35.55–$36.50 per share Prices across multiple sale executions

Key Terms

open-market sale, weighted average price, Form 4, non-derivative

4 terms

open-market sale financial

"the transaction_action field describes the trade as an open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

"transaction_type is listed as non-derivative for this Common Stock sale"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lurker Nancy

(Last) (First) (Middle)

C/O COLLEGIUM PHARMACEUTICAL, INC.

100 TECHNOLOGY CENTER DRIVE

(Street)

STOUGHTON MASSACHUSETTS 02072

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/13/2026		S		4,500	D	$35.9691(1)	18,017	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.55 to $36.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Colleen Tupper as Attorney-In-Fact For Nancy Lurker	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Nancy Lurker report at Collegium Pharmaceutical (COLL)?

Director Nancy Lurker reported selling 4,500 shares of Collegium Pharmaceutical common stock. The transaction was an open-market sale, with a weighted average price of $35.9691 per share, and left her holding 18,017 shares directly.

At what price did Nancy Lurker sell Collegium Pharmaceutical (COLL) shares?

Nancy Lurker’s reported sale used a weighted average price of $35.9691 per Collegium Pharmaceutical share. According to the filing footnote, individual trade prices ranged from $35.55 to $36.50 per share across multiple transactions on the same date.

How many Collegium Pharmaceutical (COLL) shares does Nancy Lurker hold after the sale?

After selling 4,500 shares, Nancy Lurker directly holds 18,017 shares of Collegium Pharmaceutical common stock. This post-transaction balance is stated in the Form 4 and reflects her remaining direct ownership following the reported open-market sale.

Was Nancy Lurker’s Collegium Pharmaceutical (COLL) trade a market sale or another type of transaction?

The filing identifies Nancy Lurker’s transaction as an open-market sale of Collegium Pharmaceutical common stock. It is coded as a “S” transaction, described as a sale in an open market or private transaction, rather than an option exercise, gift, or tax withholding.

Does the Collegium Pharmaceutical (COLL) insider filing show any option exercises by Nancy Lurker?

No option exercises are reported in this Form 4 for Nancy Lurker. The transaction summary shows zero derivative exercises and indicates only one non-derivative open-market sale of 4,500 common shares, with no derivative positions listed in the derivative summary.